Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Myeloid 1Lymphoid 1Dermatologic 1

Conditions

Carcinoma, Transitional Cell 9Carcinoma, Merkel Cell 7Neoplasm Metastasis 6Breast Neoplasms 6Urinary Bladder Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Neoplasms 4Melanoma 4Urethral Neoplasms 3Ureteral Neoplasms 3Skin Neoplasms 3Carcinoma, Renal Cell 3Ovarian Neoplasms 2Neuroendocrine Tumors 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Turcot syndrome 1Triple Negative Breast Neoplasms 1Thymoma 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Primary Myelofibrosis 1Peritoneal Neoplasms 1Penile Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Motor Activity 1Microsatellite Instability 1

Interventions

Rituximab 25Lenalidomide 20Cyclophosphamide 18obinutuzumab 8Vincristine 8Doxorubicin 8Prednisone 7Bendamustine Hydrochloride 7tazemetostat 6ibrutinib 6Biopsy 6venetoclax 5pembrolizumab 5fludarabine 5Specimen Handling 5CT-P10 5fludarabine phosphate 4R-CHOP protocol 4Peripheral Blood Stem Cell Transplantation 4Nivolumab 4Magnetic Resonance Spectroscopy 4Prednisolone 3Etoposide 3tocilizumab 2copanlisib 2axicabtagene ciloleucel 2atezolizumab 2acalabrutinib 2abexinostat 2Whole-Body Irradiation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Lymphoma, Follicular × avelumab × Clear all
NCT04328844 2026-03-30

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

iOnctura

Phase 1 Active not recruiting
210 enrolled
DermatologicLymphoidMyeloidOther solid neoplasmThoracic

Uveal Melanoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Mesothelioma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡